Skip to content

Pancreas lipotoxicity in type 2 diabetes: Edinburgh Diabetes Remission Study (EDRS)

Mechanisms mediating reversible lipotoxicity of the pancreas in obesity-induced type 2 diabetes: Edinburgh Diabetes Remission Study (EDRS)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN36628439
Enrollment
104
Registered
2026-01-19
Start date
2026-01-12
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes Nutritional, Metabolic, Endocrine

Interventions

All participants will follow a Total Diet Replacement (TDR) program providing ~800 kcal/day using commercially available soups and shakes for 8–12 weeks, followed by a 2-week food reintroduction phase

Sponsors

Accord (United Kingdom)
Lead Sponsor
NHS Lothian
Collaborator

Eligibility

Sex/Gender
All
Age
45 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Obese (BMI: 30-45 kg/m²) who have had T2D for less than 6 years or longer than 10 years, and are on treatment with diet alone or diet plus oral medication 2. Obese (BMI: 30-45 kg/m²) who are at the pre-diabetes stage, defined as fasting blood glucose 5.6-6.9 mmol/L 3. Obese (BMI: 30-45 kg/m²) who are non-diabetic (control group) 4. Age between 45 and 79 years inclusive 5. Men and women, however, post-menopausal women only (to exclude sex hormone effects on lipid metabolism) 6. Good communication in English (able to give informed consent and follow dietary advice) 7. Willing and able to adhere to the study protocol, including dietary intervention and scheduled follow-up visits

Exclusion criteria

Exclusion criteria: 1. Insulin therapy 2. HbA1c >12% (108 mmol/mol) 3. Weight loss >5 kg in the last 6 months 4. Recent MI (within 6 months) 5. Known cancer in the last 5 years 6. First-degree relatives of people with T2D (control group) 7. History of gestational diabetes 8. MRI contraindications (metal implants, claustrophobia) 9. Alcohol >14 units/week 10. Advanced kidney or liver disease 11. Use of steroids or antipsychotics 12. Participation in another clinical trial 13. Life expectancy <1 year 14. Allergy to local anaesthetic (for biopsy subgroup) 15. Any disorder that may jeopardise safety or compliance

Countries

Scotland, United Kingdom

Contacts

Public ContactMary Wright
edrs@ed.ac.uk+44 (0)1312426717

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 7, 2026